申请人:Merck Sharp & Dohme Corp.
公开号:US10221142B2
公开(公告)日:2019-03-05
The present invention relates to compounds according to Formula (I-1) and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
本发明涉及根据式(I-1)的化合物及其药学上可接受的盐类。此类化合物可用于治疗 RORgammaT 介导的疾病或病症。